The global opioid-induced constipation (OIC) drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor that is expected to boost the market growth includes rising number of geriatric patients as these patients use opioid analgesics such as morphine, hydromorphone, codeine, etc. as a prescription for chronic non-cancer pain which has severe adverse effects on the digestive system resulting in huge demand for OIC drugs. For instance, according to National Center for Biotechnology Information report published in November 2019, the prevalence of distention, bloating and other GI symptoms of OIC associated with the opioid analgesic medication among non-cancer patients ranges from over 40% to 60% globally every year. 

Thus, the rising volume of patient pool with opioid users demands efficient medication for the OIC ailments which is likely to boost the market during the forecast period. Furthermore, the availability of Relistor in both tablets and subcutaneous injection form, which was found to be more effective at reversing OIC compared to other drugs are likely to drive the relistor segment and contribute to the global market revenue during the forecast period.

Key Strategic Initiatives

• In February 2021, RedHill Biopharma Ltd. announced agreements with Cosmo Pharmaceuticals NV to manufacture two key products; RedHill's largest selling product in the US, Movantik(?-opioid receptor antagonist), and RHB-204, currently in a Phase 3 US study as a stand-alone, first-line orally-administered treatment for pulmonary nontuberculous mycobacteria (NTM) disease.

• In April 2020, AstraZeneca has completed an agreement to sublicense its global rights excluding Europe, Canada and Israel to RedHill Biopharma (RedHill) for Movantik (naloxegol), which is used in the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

• In April 2019, Sandoz announced that it has signed an agreement with Shionogi & Co Ltd for commercialization of Rizmoic (naldemedine), a once-daily 200-microgram oral tablet to treat opioid-induced constipation (OIC) in adult patients in the key European markets of Germany, the UK, and the Netherlands, plus right of first refusal for certain other European markets.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Product Type 

o By Prescription Type

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape: Novartis International AG, Merck & Co., Inc., and AstraZeneca plc, among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Opioid-Induced Constipation (OIC) Drug Market Report by Segment

By Product Type

• Lubiprostone

• Relistor

• Methyl Naltrexone Bromide

• Naldemedine

• Alvimopan

• Others

By Prescription Type

• Prescribed Drug

• Over-the-Counter Drug

Global Opioid-Induced Constipation (OIC) Drug Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa